New, tolerable γ-secretase inhibitor takes desmoid down a notch

Dennis P.M. Hughes, Shivaani Kummar, Alexander J. Lazar

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

A phase I trial of PF-03084014, an oral reversible γ- secretase inhibitor, in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but sometimes locally aggressive sarcoma.

Original languageEnglish (US)
Pages (from-to)7-9
Number of pages3
JournalClinical Cancer Research
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New, tolerable γ-secretase inhibitor takes desmoid down a notch'. Together they form a unique fingerprint.

Cite this